Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy
- PMID: 18025893
- DOI: 10.1097/QAD.0b013e3282f12362
Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy
Abstract
Analysis of CD4 cell responses during 48 weeks of enfuvirtide therapy after virological failure (analysis of covariance) demonstrated significant associations between V38 mutations (n = 58 subjects) and continued CD4 cell increases and between Q40 mutations (n = 8) and loss of CD4 cell benefit (+34 versus -95 cells/mul, P < 0.001). Subjects with N43 (n = 20) or other mutations (n = 48) had intermediate CD4 cell responses. These data suggest that key enfuvirtide resistance mutations may be associated with reduced viral pathogenicity in vivo.
Similar articles
-
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.J Antimicrob Chemother. 2006 Oct;58(4):714-22. doi: 10.1093/jac/dkl306. Epub 2006 Aug 5. J Antimicrob Chemother. 2006. PMID: 16891628
-
A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.J Med Virol. 2006 Oct;78(10):1312-7. doi: 10.1002/jmv.20700. J Med Virol. 2006. PMID: 16927284
-
Virological fitness of HIV in patients with resistance to enfuvirtide.AIDS. 2007 Sep 12;21(14):1974-7. doi: 10.1097/QAD.0b013e3282ef1bc8. AIDS. 2007. PMID: 17721108
-
Enfuvirtide, the first fusion inhibitor to treat HIV infection.AIDS Rev. 2005 Jul-Sep;7(3):139-47. AIDS Rev. 2005. PMID: 16302461 Review.
-
Resistance to enfuvirtide, the first HIV fusion inhibitor.J Antimicrob Chemother. 2004 Aug;54(2):333-40. doi: 10.1093/jac/dkh330. Epub 2004 Jul 1. J Antimicrob Chemother. 2004. PMID: 15231762 Review.
Cited by
-
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.Infection. 2012 Feb;40(1):69-75. doi: 10.1007/s15010-011-0223-4. Epub 2011 Dec 2. Infection. 2012. PMID: 22135137 Clinical Trial.
-
Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.Curr Top Med Chem. 2011 Dec;11(24):2947-58. doi: 10.2174/156802611798808479. Curr Top Med Chem. 2011. PMID: 22044225 Free PMC article. Review.
-
HIV-1 induced bystander apoptosis.Viruses. 2012 Nov 9;4(11):3020-43. doi: 10.3390/v4113020. Viruses. 2012. PMID: 23202514 Free PMC article. Review.
-
Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice.Virol J. 2011 Jan 21;8:34. doi: 10.1186/1743-422X-8-34. Virol J. 2011. PMID: 21255440 Free PMC article.
-
Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):572-6. doi: 10.1097/QAI.0b013e31817bbc4e. J Acquir Immune Defic Syndr. 2008. PMID: 18645515 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials